Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG

Clinical and Vaccine Immunology

Volumn 20, Issue 11, 2013, Pages 1683-1689

  Fletcher, Helen A ^a   Tanner, Rachel ^a   Wallis, Robert S ^b   Meyer, Joel ^a   Manjaly, Zita Rose ^a   Harris, Stephanie ^a   Satti, Iman ^a   Richard F, Silver ^c   Hoft, Dan ^d   Kampmann, Beate ^e,i   Walker, K Barry ^f   Dockrell, Hazel M ^g   Fruth, Uli ^h   Barker, Lew ^f   Brennan, Michael J ^f   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PFIZER INC   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f AERAS   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; BACTERIUM IDENTIFICATION; BCG VACCINATION; BLOOD ANALYSIS; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MOLECULAR DYNAMICS; MYCOBACTERIUM BOVIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPRODUCIBILITY; REVACCINATION; T LYMPHOCYTE; UNITED KINGDOM; VACCINE PRODUCTION;

ADOLESCENT; ADULT; BCG VACCINE; FEMALE; GREAT BRITAIN; HEALTHY VOLUNTEERS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; VACCINATION; YOUNG ADULT;

EID: 84886745000     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00427-13     Document Type: Article

References (25)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
2. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
3. Brennan MJ, Thole J. 2012. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 92(Suppl. 1):S6-S13.
4. Wallis RS, Palaci M, Vinhas S, Hise AG, Ribeiro FC, Landen K, Cheon SH, Song HY, Phillips M, Dietze R, Ellner JJ. 2001. A whole blood bactericidal assay for tuberculosis. J. Infect. Dis. 183:1300-1303.
5. Worku S, Hoft DF. 2000. In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guerin. Clin. Infect. Dis. 30(Suppl. 3):S257-S261.
6. Hoft DF, Worku S, Kampmann B, Whalen CC, Ellner JJ, Hirsch CS, Brown RB, Larkin R, Li Q, Yun H, Silver RF. 2002. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J. Infect. Dis. 186:1448-1457.
7. Kampmann B, Tena GN, Mzazi S, Eley B, Young DB, Levin M. 2004. Novel human in vitro system for evaluating antimycobacterial vaccines. Infect. Immun. 72:6401-6407.
8. Silver RF, Li Q, Boom WH, Ellner JJ. 1998. Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J. Immunol. 160:2408-2417.
9. Kampmann B, Gaora PO, Snewin VA, Gares MP, Young DB, Levin M. 2000. Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. J. Infect. Dis. 182:895-901.
10. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, Mahomed H, Hawkridge A, Hussey G, Kaplan G, Hanekom WA. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182:1073-1079.
11. Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Hill AV, McShane H. 2009. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One 4:e5934. doi:10.1371/journal.pone.0005934.
12. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244.
13. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, Ngwira B, Sichali L, Nazareth B, Blackwell JM, Branson K, Chaguluka SD, Donovan L, Jarman E, King E, Fine PE, Dockrell HM. 2002. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359:1393-1401.
14. Anonymous. 1972. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Bull. World Health Organ. 46:371-385.
15. Tala-Heikkila M, Nurmela T, Tala E, Tuominen J. 1991. Evaluation of the BCG revaccination programme of schoolchildren in Finland. Bull. Int. Union Tuber. Lung Dis. 66:57-59.
16. Sepulveda RL, Parcha C, Sorensen RU. 1992. Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber. Lung Dis. 73:372-377.
17. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, Hijjar MA, Dourado I, Cruz AA, Sant'Anna C, Bierrenbach AL, Barreto ML. 2005. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366:1290-1295.
18. Karonga Prevention Trial Group. 1996. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348:17-24.
19. Cunha SS, Alexander N, Barreto ML, Pereira ES, Dourado I, Maroja MF, Ichihara Y, Brito S, Pereira S, Rodrigues LC. 2008. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl. Trop. Dis. 2:e167. doi:10.1371/journal.pntd.0000167.
20. Leung CC, Tam CM, Chan SL, Chan-Yeung M, Chan CK, Chang KC. 2001. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int. J. Tuberc. Lung Dis. 5:717-723.
21. Tuomela M, Stanescu I, Krohn K. 2005. Validation overview of bioanalytical methods. Gene Ther. 12(Suppl 1):S131-S138.
22. Cheon SH, Kampmann B, Hise AG, Phillips M, Song HY, Landen K, Li Q, Larkin R, Ellner JJ, Silver RF, Hoft DF, Wallis RS. 2002. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin. Diagn. Lab. Immunol. 9:901-907.
23. Barreto ML, Pereira SM, Pilger D, Cruz AA, Cunha SS, Sant'Anna C, Ichihara MY, Genser B, Rodrigues LC. 2011. Evidence of an effect of BCGrevaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. Vaccine 29:4875-4877.
24. Hanekom WA, Dockrell HM, Ottenhoff TH, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ. 2008. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med. 5:e145. doi:10.1371/journal.pmed.0050145.
25. Parra M, Yang AL, Lim J, Kolibab K, Derrick S, Cadieux N, Perera LP, Jacobs WR, Brennan M, Morris SL. 2009. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin. Vaccine Immunol. 16:1025-1032.